Business Wire

BTS-GROUP

6.1.2020 15:37:14 CET | Business Wire | Press release

Share
BTS Acquires Rapid Learning Institute in the USA to Further Expand Its Portfolio of Digital Learning Offerings

BTS GROUP AB (publ), a leading global strategy implementation firm, has agreed to acquire the operations and all the assets of Rapid Learning Institute LLC based in Philadelphia (USA). Through its products and solutions Rapid Learning offers a differentiated approach to leadership and sales microlearning to clients in North America.

With the acquisition of Rapid Learning, BTS will gain a library of more than 200 proprietary learning modules centered on 5- to 7-minute research-backed videos, and in addition a collection of more than 2,500 articles on leadership and sales authored by the company’s editorial team. Rapid Learning’s Micro-First method to online training gives BTS thought leadership in single-concept learning facilitated by line leaders in the flow of work. The company will also bring a set of clients who subscribe to RLI’s programs or license its content. Its inside sales expertise and customer success management experience will help BTS increase its market penetration and expand its base of recurring revenue streams.

Rapid Learning was established in Philadelphia in 2008. Since then it has developed into a respected provider of leadership and sales micro-training to hundreds of clients. Its revenues over the last twelve months are approximately 2.8 MUSD. The company has 20 employees.

The executives of Rapid Learning, Stephen J. Meyer, Rob Krekstein and Michael Boyette, have agreed to stay on with BTS to drive the organization’s continued growth. An MBA graduate of the Wharton School at the University of Pennsylvania and founder of Rapid Learning, Meyer is an accomplished journalist, editor and publisher, having contributed to Forbes and Advertising Age and headed both editorial and marketing for more than two dozen employee development publications.

“We are delighted to welcome Rapid Learning to BTS,” says Henrik Ekelund, Founder & CEO of BTS. “This team creates impressive results for their clients through a comprehensive content library combined with a proven approach to leadership and sales learning in the flow of work. Together we will become an even stronger partner in the marketplace and accelerate our growth.”

“We are truly excited to become a part of the BTS family,” says Meyer, CEO of Rapid Learning. “We share the same approaches and points of view, which will make for an excellent fit. Being part of a global firm will also be a great opportunity for our customers and colleagues."

“And we believe our digital solutions and approach are a perfect complement to BTS’ current offerings,” adds Krekstein, Vice President of Sales for Rapid Learning.

“The addition of Rapid Learning to the BTS family strengthens substantially our digital content assets and thought leadership,” says Dave Ackley, Executive Vice President and Global Head of Digital at BTS. “The team brings us scalable digital solutions our clients expect and will support our efforts to build recurring license revenue.”

The acquisition includes an initial cash consideration. An additional payment will be paid out in 2023 provided the purchased operations meet specific targets 2020-2022.

BTS' strategy for acquisitions aims to create a broader base for future organic growth while actively consolidating in a highly fragmented market. Through its acquisitions, BTS also seeks to broaden its customer base and offering by bringing in new, existing and innovative services based on state-of-the-art digital technologies.

About BTS Group AB

BTS focuses on the people side of strategy, working with leaders at all levels to help them make better decisions, convert those decisions to actions and deliver results. At our core, we believe people learn best by doing. For over 30 years, we've been designing fun, powerful experiences that have a profound and lasting impact on people and their careers. We inspire new ways of thinking, build critical capabilities and unleash business success. It’s strategy made personal.

BTS is publicly traded on the Nasdaq Stockholm exchange under the symbol BTS B.

For more information, please visit www.bts.com .

Contact:

For more information, please contact: David Ackley Executive Vice President BTS Digital dave.ackley@bts.com +1.646.378.3535 Michael Wallin Head of investor relations BTS Group AB michael.wallin@bts.com +46-8-587 070 02 +46-708-78 80 19

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye